Hua Er Jie Jian Wen·2025-10-28 09:47Investment Overview - Fosun Pharma (600196) announced that its subsidiary, Fosun Pharma Industry, plans to invest 100 million RMB as a limited partner (LP) in a private equity investment fund, which aims to raise a total of 1 billion RMB. The fund will primarily invest in areas such as chemical innovative drugs, biological drugs (including vaccines), high-end medical devices (including IVD), traditional Chinese medicinal supplements, and synthetic biology [1] Fund Structure - The investment structure includes Fosun Pharma Industry committing 10% of the fund, while Chengdu Zhongchan Phase II Fund and Chengdu High-tech Source Fund each contribute 19.7%. Chengdu Jiaozi Industry Fund contributes 14.85%, and Huaren Fang Investment collectively contributes 21.75%, with the remainder coming from other investors [1] Fund Management - The fund will be managed by China Resources Capital, with a duration of 7 years, which includes a 3-year investment period and a 4-year exit period. There is an option to extend the duration by 1 year [2] Decision-Making Mechanism - The investment committee consists of 7 members, with Fosun Pharma Industry having the right to nominate 1 member. Major decisions require the approval of more than 2/3 of the committee members [3]